Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00551317 · ClinicalTrials.gov registry record · Phase 1
A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00551317 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 18 participants.
The verdict
NCT00551317, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study is being conducted to provide initial safety, tolerability, PK and PD data that will allow further studies with darapladib in Japanese patients
Interventions
- DRUG Darapladib (SB480848)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-07 |
| Est. Completion | 2007-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00551317
The ClinicalTrials.gov registry entry for NCT00551317 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Darapladib (SB480848) is the first listed.
NCT00551317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00551317 about?
NCT00551317 is a clinical study titled "A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men". This study is being conducted to provide initial safety, tolerability, PK and PD data that will allow further studies with darapladib in Japanese patients
What is the current status of trial NCT00551317?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2007-07. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00551317?
The interventions under investigation include: Darapladib (SB480848) (DRUG).
Who is sponsoring clinical trial NCT00551317?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.